Literature DB >> 23497585

Giant prolactinoma: case report and review of literature.

Masoud Rahmanian1, Hamidreza Aghaei Meybodi, Bagher Larijani, Mohammad-Reza Mohajeri-Tehrani.   

Abstract

"Invasive giant prolactinoma" is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms. Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. After 18 months, tumor size markedly reduced, associated with adrenal function and visual field improvement, but central hypogonadism and secondary hypothyroidism persisted.Previous studies showed normalization of thyrotropin secretion after treatment but it remained low in our patient even after 18 months follow up.

Entities:  

Year:  2013        PMID: 23497585     DOI: 10.1186/2251-6581-12-3

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  21 in total

1.  Primary medical therapy of micro- and macroprolactinomas in men.

Authors:  J J Pinzone; L Katznelson; D C Danila; D K Pauler; C S Miller; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Prolactin-screening tumors and hypogonadism in 22 men.

Authors:  J N Carter; J E Tyson; G Tolis; S Van Vliet; C Faiman; H G Friesen
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

3.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

Authors:  Annamaria Colao; Giovanni Vitale; Paolo Cappabianca; Francesco Briganti; Antonio Ciccarelli; Michele De Rosa; Stefano Zarrilli; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

4.  Male hyperprolactinemia:effects on fertility.

Authors:  S Segal; H Yaffe; N Laufer; M Ben-David
Journal:  Fertil Steril       Date:  1979-11       Impact factor: 7.329

5.  Giant invasive prolactinomas.

Authors:  F Y Murphy; D L Vesely; R M Jordan; S Flanigan; P O Kohler
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

6.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.

Authors:  Michele De Rosa; Stefano Zarrilli; Giovanni Vitale; Carolina Di Somma; Francesco Orio; Libuse Tauchmanova'; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  Giant prolactinomas in men: efficacy of cabergoline treatment.

Authors:  S M Corsello; G Ubertini; M Altomare; R M Lovicu; M G Migneco; C A Rota; C Colosimo
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

8.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

9.  Giant prolactinomas: clinical management and long-term follow up.

Authors:  Raj K Shrivastava; Marc S Arginteanu; Wesley A King; Kalmon D Post
Journal:  J Neurosurg       Date:  2002-08       Impact factor: 5.115

10.  Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases.

Authors:  F Gómez; F I Reyes; C Faiman
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

View more
  7 in total

1.  Breast carcinoma associated with prolactinoma: A case report.

Authors:  Yurong Zheng; Wenju Mo; Yang Yu; Dehong Zou; Xiangming He; Xianghou Xia; Jiejie Hu
Journal:  Cancer Biol Ther       Date:  2017-02-17       Impact factor: 4.742

2.  Ten-year follow-up of a giant prolactinoma.

Authors:  Vera Fernandes; Maria Joana Santos; Rui Almeida; Olinda Marques
Journal:  BMJ Case Rep       Date:  2015-11-20

3.  Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population.

Authors:  Farida Chentli; Said Azzoug; Katia Daffeur; Lina Akkache; Hadjer Zellagui; Meriem Haddad; Nadia Kalafate
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

4.  Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles.

Authors:  Derek Yecies; Abdulrazag Ajlan; John Ratliff; Jennifer Ziskin; Peter Hwang; Hannes Vogel; Laurence Katznelson; Griffith Harsh
Journal:  J Neurol Surg Rep       Date:  2015-10-29

5.  Pituitary Macroprolactinoma with Mildly Elevated Serum Prolactin: Hook Effect.

Authors:  Mahnaz Pejman Sani; Mahbube Ebrahimpur; Mohammad Reza Mohajeri-Tehrani
Journal:  Adv J Emerg Med       Date:  2018-04-28

6.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

7.  Cabergoline treatment in invasive giant prolactinoma.

Authors:  Sadeem Alsubaie; Mussa H Almalki
Journal:  Clin Med Insights Case Rep       Date:  2014-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.